世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

顔面紅斑治療薬の世界市場 2022-2026

顔面紅斑治療薬の世界市場 2022-2026


Global Facial Erythema Treatment Market 2022-2026

顔面紅斑治療の世界市場 2022-2026 Technavioは顔面紅斑治療市場を監視しており、2022年から2026年の間に1億632万ドルの成長が見込まれ、予測期間中にCAGR5.01％で進行しています。当レポートでは、顔面紅斑治療... もっと見る

　

　

出版社 出版年月 電子版価格 納期 ページ数 言語
TechNavio
テクナビオ 		2022年2月7日 US$2,500
シングルユーザーライセンス
ライセンス・価格情報
注文方法はこちら 		2営業日程度 120 英語

日本語のページは自動翻訳を利用し作成しています。


　

サマリー

顔面紅斑治療の世界市場 2022-2026
Technavioは顔面紅斑治療市場を監視しており、2022年から2026年の間に1億632万ドルの成長が見込まれ、予測期間中にCAGR5.01％で進行しています。当レポートでは、顔面紅斑治療市場の全体分析、市場規模・予測、動向、成長促進要因、課題、約25のベンダーを網羅したベンダー分析などを提供しています。
現在の世界市場のシナリオ、最新動向とドライバー、市場全体の環境に関する最新の分析を提供しています。市場は、市場プレイヤーの戦略的イニシアティブと気候条件の変化によって駆動されます。さらに、市場プレイヤーの戦略的イニシアティブは、同様に市場の成長を後押しすると予想されます。
顔面紅斑治療市場の分析には、製品セグメントと地理的景観が含まれます。
Technavioの顔面紅斑治療市場は、以下のように区分されています。
- 製品別
- 外用剤
- 経口
- 地域別
- 北米
- 欧州
- アジア
- 列
本調査では、今後数年間の顔面紅斑治療市場の成長を促進する主要な理由の一つとして、酒さの治療に対する抗生物質の高い需要を挙げています。
Technavioは、複数のソースからのデータを調査、合成、要約し、主要パラメータの分析によって、市場の詳細な図を提示します。顔面紅斑治療市場に関する当レポートの対象領域は以下の通りです。
- 顔面紅斑治療市場のサイジング
- 顔面紅斑治療市場予測
- 顔面紅斑治療市場の産業分析
Technavioの強力なベンダー分析は、顧客が市場での地位を向上できるように設計されており、これに沿って、本レポートでは、Bausch Health Companies Inc, Bayer AG, Galderma SA, GlaxoSmithKline Plc, LEO Pharma AS, Merck and Co.Inc.、Novartis AG、Pfizer Inc.、Regeneron Pharmaceuticals Inc.などです。また、顔面紅斑治療市場の分析レポートには、今後の動向と市場成長に影響を与える課題に関する情報も含まれています。これは、企業が今後訪れるすべての成長機会を戦略化し、活用できるようにするためです。
本調査は、業界の主要参加者からのインプットを含む一次情報および二次情報の客観的な組み合わせを使用して実施されました。本レポートには、主要ベンダーの分析に加え、包括的な市場およびベンダーランドスケープが含まれています。本レポートの詳細については、https://www.technavio.com/report/facial-erythema-treatment-market-industry-analysis をご覧ください。
Technavioは、利益、価格、競争、プロモーションなどの主要パラメータの分析により、複数のソースからのデータを調査、合成、総括する方法で、市場の詳細なイメージを提示します。また、業界の主要な影響力を持つ人物を特定することで、市場の様々な側面を提示しています。提示されるデータは、包括的で信頼性が高く、一次および二次にわたる広範な調査の結果です。Technavioの市場調査レポートは、正確な市場成長を予測するために、完全な競争環境と、定性的および定量的調査を用いた詳細なベンダー選定方法および分析を提供します。

ページTOPに戻る


目次

• Executive Summary
o Market Overview
• Market Landscape
o Market ecosystem
o Value chain analysis
• Market Sizing
o Market definition
o Market segment analysis
o Market size 2021
o Market outlook: Forecast for 2021 - 2026
• Five Forces Analysis
o Five Forces Summary
o Bargaining power of buyers
o Bargaining power of suppliers
o Threat of new entrants
o Threat of substitutes
o Threat of rivalry
o Market condition
• Market Segmentation by Product
o Market segments
o Comparison by Product
o Topical - Market size and forecast 2021-2026
o Oral - Market size and forecast 2021-2026
o Market opportunity by Product
• Customer landscape
• Geographic Landscape
o Geographic segmentation
o Geographic comparison
o North America - Market size and forecast 2021-2026
o Europe - Market size and forecast 2021-2026
o Asia - Market size and forecast 2021-2026
o ROW - Market size and forecast 2021-2026
o Key leading countries
o Market opportunity by geography
• Drivers, Challenges, and Trends
o Market drivers
o Market challenges
o Market trends
• Vendor Landscape
o Overview
o Landscape disruption
• Vendor Analysis
o Vendors covered
o Market positioning of vendors
o Bausch Health Companies Inc.
o Bayer AG
o Galderma SA
o GlaxoSmithKline Plc
o LEO Pharma AS
o Merck and Co. Inc.
o Novartis AG
o Pfizer Inc.
o Regeneron Pharmaceuticals Inc.
• Appendix
o Scope of the report
o Currency conversion rates for US$
o Research Methodology
o List of abbreviations

Exhibits
• 1: Key Finding 1
• 2: Key Finding 2
• 3: Key Finding 3
• 4: Key Finding 5
• 5: Key Finding 6
• 6: Key Finding 7
• 7: Key Finding 8
• 8: Parent market
• 9: Market characteristics
• 10: Offerings of vendors included in the market definition
• 11: Market segments
• 12: Global - Market size and forecast 2021 - 2026 ($ million)
• 13: Global market: Year-over-year growth 2021 - 2026 (%)
• 14: Five forces analysis 2021 & 2026
• 15: Bargaining power of buyers
• 16: Bargaining power of suppliers
• 17: Threat of new entrants
• 18: Threat of substitutes
• 19: Threat of rivalry
• 20: Market condition - Five forces 2021
• 21: Product - Market share 2021-2026 (%)
• 22: Comparison by Product
• 23: Topical - Market size and forecast 2021-2026 ($ million)
• 24: Topical - Year-over-year growth 2021-2026 (%)
• 25: Oral - Market size and forecast 2021-2026 ($ million)
• 26: Oral - Year-over-year growth 2021-2026 (%)
• 27: Market opportunity by Product
• 28: Customer landscape
• 29: Market share by geography 2021-2026 (%)
• 30: Geographic comparison
• 31: North America - Market size and forecast 2021-2026 ($ million)
• 32: North America - Year-over-year growth 2021-2026 (%)
• 33: Europe - Market size and forecast 2021-2026 ($ million)
• 34: Europe - Year-over-year growth 2021-2026 (%)
• 35: Asia - Market size and forecast 2021-2026 ($ million)
• 36: Asia - Year-over-year growth 2021-2026 (%)
• 37: ROW - Market size and forecast 2021-2026 ($ million)
• 38: ROW - Year-over-year growth 2021-2026 (%)
• 39: Key leading countries
• 40: Market opportunity by geography ($ million)
• 41: Impact of drivers and challenges
• 42: Vendor landscape
• 43: Landscape disruption
• 44: Industry risks
• 45: Vendors covered
• 46: Market positioning of vendors
• 47: Bausch Health Companies Inc. - Overview
• 48: Bausch Health Companies Inc. - Business segments
• 49: Bausch Health Companies Inc. - Key offerings
• 50: Bausch Health Companies Inc. - Key customers
• 51: Bausch Health Companies Inc. - Segment focus
• 52: Bayer AG - Overview
• 53: Bayer AG - Business segments
• 54: Bayer AG - Key offerings
• 55: Bayer AG - Key customers
• 56: Bayer AG - Segment focus
• 57: Galderma SA - Overview
• 58: Galderma SA - Product and service
• 59: Galderma SA - Key offerings
• 60: Galderma SA - Key customers
• 61: Galderma SA - Segment focus
• 62: GlaxoSmithKline Plc - Overview
• 63: GlaxoSmithKline Plc - Business segments
• 64: GlaxoSmithKline Plc - Key offerings
• 65: GlaxoSmithKline Plc - Key customers
• 66: GlaxoSmithKline Plc - Segment focus
• 67: LEO Pharma AS - Overview
• 68: LEO Pharma AS - Business segments
• 69: LEO Pharma AS - Key offerings
• 70: LEO Pharma AS - Key customers
• 71: LEO Pharma AS - Segment focus
• 72: Merck and Co. Inc. - Overview
• 73: Merck and Co. Inc. - Business segments
• 74: Merck and Co. Inc. - Key offerings
• 75: Merck and Co. Inc. - Key customers
• 76: Merck and Co. Inc. - Segment focus
• 77: Novartis AG - Overview
• 78: Novartis AG - Business segments
• 79: Novartis AG - Key offerings
• 80: Novartis AG - Key customers
• 81: Novartis AG - Segment focus
• 82: Pfizer Inc. - Overview
• 83: Pfizer Inc. - Business segments
• 84: Pfizer Inc. - Key offerings
• 85: Pfizer Inc. - Key customers
• 86: Pfizer Inc. - Segment focus
• 87: Regeneron Pharmaceuticals Inc. - Overview
• 88: Regeneron Pharmaceuticals Inc. - Product and service
• 89: Regeneron Pharmaceuticals Inc. - Key offerings
• 90: Regeneron Pharmaceuticals Inc. - Key customers
• 91: Regeneron Pharmaceuticals Inc. - Segment focus
• 92: Currency conversion rates for US$
• 93: Research Methodology
• 94: Validation techniques employed for market sizing
• 95: Information sources
• 96: List of abbreviations

　

ページTOPに戻る


　

Summary

Global Facial Erythema Treatment Market 2022-2026
Technavio has been monitoring the facial erythema treatment market and it is poised to grow by $ 106.32 mn during 2022-2026, progressing at a CAGR of 5.01% during the forecast period. Our report on the facial erythema treatment market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by strategic initiatives of market players and changing climatic conditions. In addition, strategic initiatives of market players is anticipated to boost the growth of the market as well.
The facial erythema treatment market analysis includes the product segment and geographic landscape.
Technavio's facial erythema treatment market is segmented as below:
• By Product
• Topical
• Oral
• By Geography
• North America
• Europe
• Asia
• ROW
This study identifies the high demand for antibiotics for the treatment of rosaceaas one of the prime reasons driving the facial erythema treatment market growth during the next few years.
Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our report on facial erythema treatment market covers the following areas:
• Facial erythema treatment market sizing
• Facial erythema treatment market forecast
• Facial erythema treatment market industry analysis
Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading facial erythema treatment market vendors that include Bausch Health Companies Inc., Bayer AG, Galderma SA, GlaxoSmithKline Plc, LEO Pharma AS, Merck and Co. Inc., Novartis AG, Pfizer Inc., and Regeneron Pharmaceuticals Inc. Also, the facial erythema treatment market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors. For further information on this report, please visit - https://www.technavio.com/report/facial-erythema-treatment-market-industry-analysis
Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.



ページTOPに戻る


Table of Contents

• Executive Summary
o Market Overview
• Market Landscape
o Market ecosystem
o Value chain analysis
• Market Sizing
o Market definition
o Market segment analysis
o Market size 2021
o Market outlook: Forecast for 2021 - 2026
• Five Forces Analysis
o Five Forces Summary
o Bargaining power of buyers
o Bargaining power of suppliers
o Threat of new entrants
o Threat of substitutes
o Threat of rivalry
o Market condition
• Market Segmentation by Product
o Market segments
o Comparison by Product
o Topical - Market size and forecast 2021-2026
o Oral - Market size and forecast 2021-2026
o Market opportunity by Product
• Customer landscape
• Geographic Landscape
o Geographic segmentation
o Geographic comparison
o North America - Market size and forecast 2021-2026
o Europe - Market size and forecast 2021-2026
o Asia - Market size and forecast 2021-2026
o ROW - Market size and forecast 2021-2026
o Key leading countries
o Market opportunity by geography
• Drivers, Challenges, and Trends
o Market drivers
o Market challenges
o Market trends
• Vendor Landscape
o Overview
o Landscape disruption
• Vendor Analysis
o Vendors covered
o Market positioning of vendors
o Bausch Health Companies Inc.
o Bayer AG
o Galderma SA
o GlaxoSmithKline Plc
o LEO Pharma AS
o Merck and Co. Inc.
o Novartis AG
o Pfizer Inc.
o Regeneron Pharmaceuticals Inc.
• Appendix
o Scope of the report
o Currency conversion rates for US$
o Research Methodology
o List of abbreviations

Exhibits
• 1: Key Finding 1
• 2: Key Finding 2
• 3: Key Finding 3
• 4: Key Finding 5
• 5: Key Finding 6
• 6: Key Finding 7
• 7: Key Finding 8
• 8: Parent market
• 9: Market characteristics
• 10: Offerings of vendors included in the market definition
• 11: Market segments
• 12: Global - Market size and forecast 2021 - 2026 ($ million)
• 13: Global market: Year-over-year growth 2021 - 2026 (%)
• 14: Five forces analysis 2021 & 2026
• 15: Bargaining power of buyers
• 16: Bargaining power of suppliers
• 17: Threat of new entrants
• 18: Threat of substitutes
• 19: Threat of rivalry
• 20: Market condition - Five forces 2021
• 21: Product - Market share 2021-2026 (%)
• 22: Comparison by Product
• 23: Topical - Market size and forecast 2021-2026 ($ million)
• 24: Topical - Year-over-year growth 2021-2026 (%)
• 25: Oral - Market size and forecast 2021-2026 ($ million)
• 26: Oral - Year-over-year growth 2021-2026 (%)
• 27: Market opportunity by Product
• 28: Customer landscape
• 29: Market share by geography 2021-2026 (%)
• 30: Geographic comparison
• 31: North America - Market size and forecast 2021-2026 ($ million)
• 32: North America - Year-over-year growth 2021-2026 (%)
• 33: Europe - Market size and forecast 2021-2026 ($ million)
• 34: Europe - Year-over-year growth 2021-2026 (%)
• 35: Asia - Market size and forecast 2021-2026 ($ million)
• 36: Asia - Year-over-year growth 2021-2026 (%)
• 37: ROW - Market size and forecast 2021-2026 ($ million)
• 38: ROW - Year-over-year growth 2021-2026 (%)
• 39: Key leading countries
• 40: Market opportunity by geography ($ million)
• 41: Impact of drivers and challenges
• 42: Vendor landscape
• 43: Landscape disruption
• 44: Industry risks
• 45: Vendors covered
• 46: Market positioning of vendors
• 47: Bausch Health Companies Inc. - Overview
• 48: Bausch Health Companies Inc. - Business segments
• 49: Bausch Health Companies Inc. - Key offerings
• 50: Bausch Health Companies Inc. - Key customers
• 51: Bausch Health Companies Inc. - Segment focus
• 52: Bayer AG - Overview
• 53: Bayer AG - Business segments
• 54: Bayer AG - Key offerings
• 55: Bayer AG - Key customers
• 56: Bayer AG - Segment focus
• 57: Galderma SA - Overview
• 58: Galderma SA - Product and service
• 59: Galderma SA - Key offerings
• 60: Galderma SA - Key customers
• 61: Galderma SA - Segment focus
• 62: GlaxoSmithKline Plc - Overview
• 63: GlaxoSmithKline Plc - Business segments
• 64: GlaxoSmithKline Plc - Key offerings
• 65: GlaxoSmithKline Plc - Key customers
• 66: GlaxoSmithKline Plc - Segment focus
• 67: LEO Pharma AS - Overview
• 68: LEO Pharma AS - Business segments
• 69: LEO Pharma AS - Key offerings
• 70: LEO Pharma AS - Key customers
• 71: LEO Pharma AS - Segment focus
• 72: Merck and Co. Inc. - Overview
• 73: Merck and Co. Inc. - Business segments
• 74: Merck and Co. Inc. - Key offerings
• 75: Merck and Co. Inc. - Key customers
• 76: Merck and Co. Inc. - Segment focus
• 77: Novartis AG - Overview
• 78: Novartis AG - Business segments
• 79: Novartis AG - Key offerings
• 80: Novartis AG - Key customers
• 81: Novartis AG - Segment focus
• 82: Pfizer Inc. - Overview
• 83: Pfizer Inc. - Business segments
• 84: Pfizer Inc. - Key offerings
• 85: Pfizer Inc. - Key customers
• 86: Pfizer Inc. - Segment focus
• 87: Regeneron Pharmaceuticals Inc. - Overview
• 88: Regeneron Pharmaceuticals Inc. - Product and service
• 89: Regeneron Pharmaceuticals Inc. - Key offerings
• 90: Regeneron Pharmaceuticals Inc. - Key customers
• 91: Regeneron Pharmaceuticals Inc. - Segment focus
• 92: Currency conversion rates for US$
• 93: Research Methodology
• 94: Validation techniques employed for market sizing
• 95: Information sources
• 96: List of abbreviations

　

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野の最新刊レポート

  • 本レポートと同分野の最新刊レポートはありません。

TechNavio社の